

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: DIXIT et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: Interleukin-1 β Converting Enzyme Like
Apoptotic Protease-6

Attorney Docket No.: PF335D2

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits and prior to fee calculation, please amend the above-captioned application as follows:

In the Specification:

Pages 64-71, please delete the Sequence Listing and insert therefor the attached substitute Sequence Listing.

REMARKS

The specification has been amended to replace the sequence Listing with the substitute sequence Listing submitted herewith.

No new matter has been added by way of this amendment.


Conclusion

Entry of the above amendments and remarks is respectfully requested.

No believed due in connection with the submission of this paper. However, if the Commissioner should determine otherwise, please charge the fees to our Deposit Account No. 08-3425.

Respectfully submitted,

Date: September 24, 2001


Kenley K. Hoover (Reg. No. 40,302)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Telephone: (301) 610-5771

KKH/lcc